Seald AS is a biotech company developing an innovative personalised approach to treating bile duct cancer. Bile duct cancer is a rare, but very deadly form of cancer. The five-year survival rate is two to five per cent, the mean life expectancy on standard chemotherapy is only 11,5 months. A small number of patients are eligible for surgery, and more than 50 per cent of these relaps.
Welcome to Seald AS
Addressing uncertainty. Unravelling cures.
Seald AS is a biotech company developing an innovative personalised approach for treating bile duct cancer. Bile duct cancer is a rare, but very deadly form of cancer afflicting three per cent of people with cancer in the digestive system. Utilising a whole new approach, Seald AS aspires to find the right treatment for the individual patient based on a methodology combining molecular biomarkers, DNA sequencing, ex-vivo drug sensitivity analysis and living xenograft animal models. Together with our research partners Institute of Cancer Research, The Radium Hospital, Seald plan to run the first clinical study at the renowned Norwegian Radium Hospital in 2019.
Renowned partnersRecognised scientific actors on board
Innovative approachTo quickly identify effective treatment using evidence-based tests using the patients own living cancer cells
Unmet medical needBile duct cancer is aggressiv and many patients are treated with therapies that do not work
Large, global marketEstimated global pharma market is USD 2,1–4,2 billion, in addition to the markets for diagnostics and platform technology.I
Innovative therapies for bile duct cancer
The company develops novel therapies for bile duct cancer, also called cholangiocarcinoma (CCA). This is done by employing a multidisciplinary approach to developing completely personalised cures, through unraveling both new diagnostics, medications and a new method for personalised treatments.
Clinical trial to start in 2019
Clinical development will be conducted in collaboration with both Norwegian and American clinical research centres. These trials will be conducted at the Clinical Cancer Research Unit (Phase I unit) at the Norwegian Radium Hospital, Oslo University Hospital. The observational study is planned to commence in 2019.